Olivia Brayer
Stock Analyst at Cantor Fitzgerald
(3.13)
# 1,126
Out of 4,944 analysts
103
Total ratings
45%
Success rate
2.17%
Average return
Main Sectors:
Stocks Rated by Olivia Brayer
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VRNA Verona Pharma | Maintains: Overweight | $90 → $100 | $105.20 | -4.94% | 1 | Jun 11, 2025 | |
| UTHR United Therapeutics | Initiates: Overweight | $405 | $309.72 | +30.76% | 1 | Jun 2, 2025 | |
| VNDA Vanda Pharmaceuticals | Assumes: Overweight | $13 | $4.36 | +198.17% | 1 | May 14, 2025 | |
| BMRN BioMarin Pharmaceutical | Reiterates: Overweight | $90 | $58.30 | +54.37% | 15 | Feb 20, 2025 | |
| VRTX Vertex Pharmaceuticals | Reiterates: Overweight | $480 | $395.92 | +21.24% | 22 | Feb 11, 2025 | |
| BMY Bristol-Myers Squibb Company | Maintains: Neutral | $50 → $55 | $47.85 | +14.94% | 9 | Feb 4, 2025 | |
| GILD Gilead Sciences | Reiterates: Neutral | $80 | $120.14 | -33.41% | 10 | Dec 11, 2024 | |
| OMER Omeros | Reiterates: Neutral | n/a | $4.27 | - | 1 | Nov 14, 2024 | |
| REGN Regeneron Pharmaceuticals | Reiterates: Neutral | $1,015 | $561.55 | +80.75% | 8 | Oct 23, 2024 | |
| AMGN Amgen | Reiterates: Overweight | $405 | $289.33 | +39.98% | 2 | Oct 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $220 | $432.52 | -49.14% | 23 | Oct 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $10 | $12.01 | -16.74% | 5 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $6.5 | $3.73 | +74.26% | 4 | May 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $72 | $57.33 | +25.59% | 1 | Apr 13, 2023 |
Verona Pharma
Jun 11, 2025
Maintains: Overweight
Price Target: $90 → $100
Current: $105.20
Upside: -4.94%
United Therapeutics
Jun 2, 2025
Initiates: Overweight
Price Target: $405
Current: $309.72
Upside: +30.76%
Vanda Pharmaceuticals
May 14, 2025
Assumes: Overweight
Price Target: $13
Current: $4.36
Upside: +198.17%
BioMarin Pharmaceutical
Feb 20, 2025
Reiterates: Overweight
Price Target: $90
Current: $58.30
Upside: +54.37%
Vertex Pharmaceuticals
Feb 11, 2025
Reiterates: Overweight
Price Target: $480
Current: $395.92
Upside: +21.24%
Bristol-Myers Squibb Company
Feb 4, 2025
Maintains: Neutral
Price Target: $50 → $55
Current: $47.85
Upside: +14.94%
Gilead Sciences
Dec 11, 2024
Reiterates: Neutral
Price Target: $80
Current: $120.14
Upside: -33.41%
Omeros
Nov 14, 2024
Reiterates: Neutral
Price Target: n/a
Current: $4.27
Upside: -
Regeneron Pharmaceuticals
Oct 23, 2024
Reiterates: Neutral
Price Target: $1,015
Current: $561.55
Upside: +80.75%
Amgen
Oct 22, 2024
Reiterates: Overweight
Price Target: $405
Current: $289.33
Upside: +39.98%
Oct 11, 2024
Reiterates: Neutral
Price Target: $220
Current: $432.52
Upside: -49.14%
Sep 16, 2024
Reiterates: Overweight
Price Target: $10
Current: $12.01
Upside: -16.74%
May 9, 2024
Reiterates: Overweight
Price Target: $6.5
Current: $3.73
Upside: +74.26%
Apr 13, 2023
Initiates: Overweight
Price Target: $72
Current: $57.33
Upside: +25.59%